EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors

Toshihiko Doi iD, Noboru Yamamoto, Shuichi Ohkubo iD

Future Oncology · 2024

DOI: 10.2217/fon-2022-1172 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Oncology, 2024. Verfasst von Toshihiko Doi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, National Cancer Centre Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Antineoplastic Agents, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taiho Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pimitespib (TAS-116) is the first heat shock protein 90 (HSP90) inhibitor approved in Japan, and it is indicated for the treatment of gastrointestinal stromal tumors (GIST) that have progressed after treatment with imatinib, sunitinib and regorafenib. This review describes the preclinical and clinical research with pimitespib, including its mechanism of action, pharmacokinetics, clinical antitumour activity and safety. In a phase III study, pimitespib significantly prolonged progression-free survival compared with placebo (median 2.8 vs 1.4 months; hazard ratio 0.51; 95% CI 0.30-0.87; p = 0.006). Common treatment-related adverse events were diarrhoea, decreased appetite, increase in serum creatinine, malaise, nausea and eye disorders. The efficacy and safety of pimitespib are being investigated in other tumour types and in combination with other anticancer therapies. What is this article about? This article provides information about pimitespib, a drug that recently became available in Japan for the treatment of advanced gastrointestinal stromal tumors, or ‘GISTs’. GISTs are a type of cancer found in the gastrointestinal tract, and those that are considered ‘advanced’ have stopped responding to other treatments and have spread to other parts of the body. What have studies shown? Pimitespib works in a way unlike other drug treatments for cancer – it inhibits a protein called heat shock protein 90, and this stops cancer cells from developing and growing. Pimitespib is taken by mouth. Studies in Japanese patients with advanced GISTs showed an increase in the time taken for the cancer to progress further and in the length of time that patients survived among those treated with pimitespib, compared with patients who did not receive the drug. These studies also found that pimitespib was not associated with serious side effects, although diarrhoea occurred frequently. Eye disorders developed in some patients, but they could be managed by interrupting or stopping treatment with pimitespib. Pimitespib is also being studied for the treatment of other cancers, alone and in combination with other anticancer drugs. What conclusions can be made from these studies? There are very few treatments available for patients with advanced GISTs and, therefore, pimitespib is an important new option for such patients in Japan. If the results of ongoing studies are positive, pimitespib may become a treatment option for a wider range of cancer patients in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsAntineoplastic AgentsGastrointestinal NeoplasmsHumansImatinib MesylateSunitinibJapanProtein Kinase Inhibitors

Stichwörter der Autor:innen

HSP90 inhibitorsTAS-116gastrointestinal stromal tumorsheat shock proteinsocular safetypimitespibsurvival

Substanzen

Antineoplastic AgentsImatinib MesylateSunitinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Experimental Therapeutics, National Cancer Centre Hospital East, Kashiwa, Japan.
  • Department of Experimental Therapeutics, National Cancer Centre Hospital, Tokyo, Japan.
  • Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Ibaraki, Japan.

ORCID-Profile: Toshihiko Doi, Shuichi Ohkubo

Förderung

  • Taiho Pharmaceuticals

Zitieren

APA

Doi, T., Yamamoto, N., & Ohkubo, S. (2024). Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors. Future Oncology. https://doi.org/10.2217/fon-2022-1172

Vancouver

Doi T, Yamamoto N, Ohkubo S. Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors. Future Oncology. 2024. doi:10.2217/fon-2022-1172

BibTeX
@article{Doi2024,
  author = {Doi, Toshihiko and Yamamoto, Noboru and Ohkubo, Shuichi},
  title = {Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2022-1172}
}
Kostenlos starten →